Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocolY K Onno Teng, Paul P. Tak, Ian N Bruce et al.|BMJ Open|2019Cited by 111
A Safety Monitoring Procedure for a Clinical Drug Development Program, with Application to the Assessment of a Novel COX-2 InhibitorKim Bolland, Mary Oldham, John Whitehead|Journal of Biopharmaceutical Statistics|2008Cited by 0